Negotiating the "bio-identicals" controversy

Published: April, 2008

The FDA says some compounding pharmacies have stepped over the line.

In January 2008, the FDA sent letters to seven compounding pharmacies, warning them not to claim that their custom-made hormone therapy products are safer or more effective than conventional hormone therapy or can treat or prevent conditions such as Alzheimer's disease, breast cancer, heart disease, and depression — claims for which there is no scientific proof. The agency also wants compounders to stop using the term "bio-identical," on the grounds that it misleads women and health care professionals by incorrectly suggesting that their mixtures are more "natural" than standard hormone therapy or exactly the same as hormones made by the body. The warning letters also told compounders to discontinue the use of estriol, a weak form of estrogen produced during pregnancy. Estriol is not approved for clinical use, but it has been incorporated in many compounded hormone products (including the popular combinations Biest and Triest).

To continue reading this article, you must log in.
  • Research health conditions
  • Check your symptoms
  • Prepare for a doctor's visit or test
  • Find the best treatments and procedures for you
  • Explore options for better nutrition and exercise

New subscriptions to Harvard Health Online are temporarily unavailable. Click the button below to learn about our other subscription offers.

Learn More »